Healthcare shares today are mixed in pre-market trade. Shares of
Agenus Inc. (
) soared in Thursday's premarket session, bouncing off a 52-week
low hit Wednesday, as the biotechnology company focused on
treatments for cancers and infectious diseases released top-line
results showing a Phase 2 study of HerpV, a vaccine candidate for
the treatment of patients with herpes simplex virus-2, met its
The shares were up 27% at $3.05 in recent premarket trading.
They have a 52-week range of $2.40 to $5.40, with the low end of
that range set Wednesday.
And, NovaBay Pharmaceuticals, Inc. (
), a clinical-stage biopharmaceutical company developing
non-antibiotic antimicrobial products, said the auriclosene Phase
2b clinical study of impetigo has been completed.
NBY is down 51% at $0.82 per share, hitting a new 52-week
While the study showed that auriclosene is safe and well
tolerated, it did not meet its primary clinical endpoint. NovaBay
and its partner Galderma are examining the results from this study
and expect to use the findings to guide the future course of the
clinical development for auriclosene. NovaBay expects to provide an
update in the near future.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.